Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.304
Neutral
RSI(14)
62.593
Neutral
STOCH(KDJ)(9,3,3)
78.965
Buy
ATR(14)
5.497
High Vlolatility
CCI(14)
116.689
Buy
Williams %R
13.621
Overbought
TRIX(12,20)
0.645
Sell
StochRSI(14)
79.963
Buy
Search
Oruka Therapeutics Inc
ORKAAdd to Watchlist
96.510USD
-1.350-1.38%
Close 07-31 16:00（ET）Quotes delayed by 15 min
4.84BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-1.38%
5 Days
+4.72%
1 Month
+3.45%
6 Months
+181.95%
Year to Date
+218.41%
1 Year
+609.63%
Key Figures
98.800Open
99.000High
758.75KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.51%Turnover Ratio
97.860Prev. Close
92.720Low
55.90MTurnover
LossP/E Static
10.01P/B
0.00%Div Yield TTM
-26.37%ROA
91.00052wk High
0.84Volume Ratio
-83.72MNet Profit
50.17MShares
-2.3843EPS TTM
-0.23Beta
-27.50%ROE
10.63552wk Low
6.42%Amplitude
--Gross Margin
4.84BMarket Cap
3.84Reward/Risk
4.61%Risk Rate
TradingKey Stock Score of Oruka Therapeutics Inc
Currency: USD Updated: 2026-07-31Key Insights
Oruka Therapeutics Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 79 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 146.85.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current strong trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Oruka Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Oruka Therapeutics Inc Highlights
StrengthsRisks
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -40.48, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 56.79M shares, increasing 10.95% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 2.26M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.50.
Analyst Rating
Based on
14
analysts
Strong Buy
Current Rating
146.846
Target Price
+66.74%
Upside Space
Oruka Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
14
analysts
Strong Buy
Current Rating
146.846
Target Price
+66.74%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Oruka Therapeutics Inc
ORKA
14
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
92.618
Buy
MA10
92.576
Buy
MA20
89.364
Buy
MA50
77.962
Buy
MA100
67.483
Buy
MA200
49.016
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Oruka Therapeutics Inc Info
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
Ticker SymbolORKA
CompanyOruka Therapeutics Inc
CEOKlein (Lawrence Otto)
Websitehttps://orukatx.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Oruka Therapeutics Inc (ORKA)?
The current price of Oruka Therapeutics Inc (ORKA) is 96.51.
What is the symbol of Oruka Therapeutics Inc?
The ticker symbol of Oruka Therapeutics Inc is ORKA.
What is the 52-week high of Oruka Therapeutics Inc?
The 52-week high of Oruka Therapeutics Inc is 91.00.
What is the 52-week low of Oruka Therapeutics Inc?
The 52-week low of Oruka Therapeutics Inc is 10.63.
What is the market capitalization of Oruka Therapeutics Inc?
The market capitalization of Oruka Therapeutics Inc is 4.84B.
Is Oruka Therapeutics Inc (ORKA) currently rated as Buy, Hold, or Sell?
According to analysts, Oruka Therapeutics Inc (ORKA) has an overall rating of STRONG BUY, with a price target of 146.85.
What is the Earnings Per Share (EPS TTM) of Oruka Therapeutics Inc (ORKA)?
The Earnings Per Share (EPS TTM) of Oruka Therapeutics Inc (ORKA) is -2.31.